Notice of Special Interest (NOSI): Accelerate Dissemination of Emerging Glycoscience Tools through Collaborations Between Developers and Early Adopters

Notice Number: NOT-RM-19-012

Key Dates
Release Date: July 15, 2019
First Available Due Date: August 15, 2019
Expiration Date: August 16, 2019

Related Announcements
PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Issued by
Office of Strategic Coordination (Common Fund)

Purpose

Glycans are saccharides that can be attached to a wide variety of biological molecules to augment their function. They play important roles in virtually all biological processes including early development, immune regulation, disease processes, and vaccine development. Often, glycans are the predominant molecule on the cell surface and serve as the first point of contact between cells, the extracellular matrix and pathogens. Although carbohydrates play important roles in both normal and disease processes, their complexity presents challenges to their study by most biomedical researchers.

To address these challenges, the NIH Common Fund Glycoscience Program (CF-GSP) was started in 2015. The program supports the development of methodologies, tools, and resources to simplify and expand the synthesis of large libraries of glycans; for glycan identification, tracking, manipulation, and functional analysis; and informatics to integrate gene, protein, and glycan datasets. Access to robust glycan libraries and tools to study N- and O-glycosylation, proteoglycans, polysaccharides, and glycolipids are expected to facilitate studies of the roles these molecules play in normal cellular processes and in disease.

Both the program’s resources and the tools being produced by the CF-GSP’s investigators are available to all NIH funded investigators as well as the broader scientific community for exploration of the roles of carbohydrates in normal and disease processes. Chemical standards and reference data developed by investigators in the Glycoscience Program are freely available and can be found here: https://commonfund.nih.gov/Glycoscience/programresources

In addition, NIH funded investigators are encouraged to Beta test/adapt the many tools and technologies being developed by the CF-GSP for use in their own research programs. https://commonfund.nih.gov/Glycoscience/fundedresearch

Research Objectives

To encourage broad adoption of CF-GSP tools/technologies, the Common Fund will support administrative supplements to NIH-supported investigators who are NOT part of the Glycoscience program and NOT established glycoscientists. These will be one-year administrative supplements to existing NIH awards for:

  • Non-specialists who need access to glycobiology tools
  • Engaging core facilities to adopt glyco tools/technologies developed by the CF-GSP
  • Intensive collaboration between CF-GSP technology/methodology developers and non-glycoscientist adopters
  • Validation and refinement of CF-GSP technologies and methodologies
  • Faster demonstration of effectiveness of CF-GSP technologies and methodologies
  • Feedback for documentation and tutorials related to the technologies and methodologies developed by the CF-GSP

Application and Submission Information

Budget

To be eligible, the parent award must be able to receive funds in FY19 (Oct. 1, 2018- Sept. 30, 2019) and not be in a no-cost extension period at the time of the award.

One-time supplement budget requests cannot exceed $100,000/year direct costs. It is anticipated that 3-5 awards will be made, subject to availability of funds in FY2019.

Eligible Individuals (Program Director/Principal Investigator)

Individual(s) must hold an active grant or cooperative agreement that can be supplemented. For supplements to parent awards that include multiple PDs/PIs, a single supplement may be requested (for use by any or all of the PDs/PIs in accordance with the existing leadership plan) and submitted by the awardee institution of the parent award.

Supplements to Grants/Cooperative Agreements:

Applications for this initiative must be submitted using PA-18-591 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) or its subsequent reissued equivalent.

All instructions in the SF424 (R&R) Application Guide and PA-18-591 must be followed, with the following additions:

  • Application Due Date(s) – August 15, 2019, by 5:00 PM local time of applicant organization.
  • For funding consideration, applicants must include "NOT-RM-19-012" (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
  • Requests may be for one year of support only.
  • The Research Strategy section of the application is limited to 5 pages.
  • Electronic submissions are strongly preferred for this funding opportunity. However, the process for Streamlined Submissions using the eRA Commons cannot be used for this initiative.
  • Applicants are strongly encouraged to notify the program contact at the Institute supporting the parent award that a request has been submitted to this FOA in order to facilitate efficient processing of the request.
  • Applications should describe how the tool(s)/technology developed by the NIH Common Fund Glycoscience program will be adopted for advancing (within scope) the investigators own funded research.
  • Does the proposed adoptor - developer collaboration have significant potential to succeed through beta testing to full adoption?

Administrative Evaluation Process

Each IC will conduct administrative reviews of applications submitted to their IC separately. The most meritorious applications submitted for consideration will be supported based upon availability of funds.

Administrative Criteria

1. Is the work proposed within the scope of the active award?

2. Does the work proposed address one of the components listed under the IC-specific research objectives?

3. Is there a collaboration between the non-glycoscience investigator and the CF-GSP glycoscience investigator that will lead to the beta testing/adoption of a CF-GSP tool and/or technology?

4. Does the work proposed have scientific merit?

5. Is the work likely to stimulate additional understanding of glycoscience mechanisms?

Additional Information:

It is strongly recommended that the applicants contact their respective program officers at the Institute supporting the parent award to:

  • confirm ahead of time that the supplement falls within scope of the parent award;
  • request the requirements of the IC for submitting applications for administrative supplements

Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact and discuss their proposed research/aims with the CF-GSP contact listed on this NOSI in advance of the grant receipt date.

Following submission, applicants are strongly encouraged to notify the program contact at the IC supporting the parent award that a request has been submitted in response to this FOA in order to facilitate efficient processing of the request.

Inquiries

Please direct all inquiries to:

Pamela Marino, Ph.D.
National Institute of General Medical Sciences (NIGMS)
Telephone: 301-594-5939
Email: MARINOP@nigms.nih.gov